ArticleMedicine2026
Circulating proteins and risk of small vessel stroke: A two-sample Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To identify promising circulating biomarkers for small vessel stroke (SVS), we applied Mendelian randomization (MR) design to systematically screen circulating proteins for potential development of SVS. We performed two-sample MR analyses to estimate the associations between 4782 human circulating proteins (including immunity-related proteins) and risk of SVS. We selected 359 circulating proteins in MR estimation (4422 circulating proteins with <3 SNPs were excluded) with totally 5368 European descents. Summary statistics for SVS originated from the MEGASTROKE Consortium, involving 446,696 participants. MR analyses were conducted to estimate associations of circulating proteins with SVS. After inverse variance weighting and sensitivity analysis filtration, GRAMD1C causally increased the risk of SVS (OR = 2.86, 95% CI = 1.71-4.76, P = 5.61e-05). In addition, PTGR1 (OR = 1.15, 95% CI = 1.04-1.27, P = 6.65e-03) presented a suggestive association with SVS. In this two-sample MR investigation, a significant association was identified between the cholesterol transporter GRAMD1C and SVS, indicating its potential as a promising target for diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.